Andre Ywata de Carvalho

Andre Ywata de Carvalho

Auto-generated profile, based on publicly available information

Andre Ywata de Carvalho

Head and Neck Surgery and Otorhinolaryngology Department, A. C. Camargo Cancer Center, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Acta Otorhinolaryngologica Italica
Verified
Journal Article
Open access
PDF file
ACAndre Ywata de Carvalho
Andre Ywata de Carvalho
HKHugo Fontan Kohler
Hugo Fontan Kohler
CGCamila Couto Gomes
Camila Couto Gomes
JVJose Guilherme Vartanian
Jose Guilherme Vartanian
LKLuiz Paulo Kowalski
Luiz Paulo Kowalski
Objective. The incidence of papillary thyroid carcinoma (PTC) has increased in recent years and its treatment remains controversial. The objective of this study is to identify clinicopathological predictive factors of tumour recurrence.Methods. We retrospectively analysed 4,085 patients who underwent thyroidectomy for PTC from 1996 to 2015. Patients were stratified according to American Thyroid Association (ATA) risk categories and clinicopathological features were evaluated to identify independent factors for recurrence.Results. After a mean follow-up of 58.7 (range 3-256.5) months, tumour recurrence was diagnosed in 176 (4.3%) patients, mostly in lymph nodes. Distant metastasis occurred in 18 patients (0.4%). There were 3 (0.1%) cancer-related deaths. Multivariate analysis showed that tumour size >10 mm, multifocality, extrathyroidal extension and lymph node metastasis (all, P < 0.001) were independent risk factors for recurrence. Further, recurrence was identified in 1.6% of the ATA low-risk, 7.4% of the intermediate-risk and 22.7% of the high-risk patients (P < 0.001). Conclusions. In PTC patients, tumour size >10 mm, multifocality, extrathyroidal extension and presence of lymph node metastasis as well as the ATA recurrence staging system effectively predict recurrence.

30 September 2020 in International Archives of Otorhinolaryngology
Verified
Journal Article
Open access
PDF file
ACAndre Ywata de Carvalho
Andre Ywata de Carvalho
CGCamila Couto Gomes
Camila Couto Gomes
TCThiago Celestino Chulam
Thiago Celestino Chulam
Jose VartanianJose Vartanian
Jose Vartanian
GCGenival Barbosa de Carvalho
Genival Barbosa de Carvalho
Luiz P. KowalskiLuiz P. Kowalski
Luiz P. Kowalski
Introduction Postoperative neck hematoma (PNH) is an uncommon but potentially-lethal complication of thyroid surgery. Objective To identify the risk factors for postthyroidectomy hematoma requiring reoperation, the timing, the source of the bleeding, the related respiratory distress requiring tracheotomy, and the late outcomes. Methods We retrospectively analyzed the records of 5,900 consecutive patients submitted to surgery for thyroid diseases at a single institution. Results In total, PNH occurred in 62 (1.1%) patients. Most cases of bleeding occurred within the first 6 hours after thyroidectomy, but 12.5% of the hematomas were observed after 24 hours. Obvious bleeding points were detected in 58.1% of the patients during the reoperation, with inferior thyroid artery branches and superior thyroid vessels being the most frequent bleeding sources. Only two patients required urgent tracheostomy. There were no hematoma-related deaths. Permanent hypoparathyroidism and recurrent laryngeal nerve injury are more frequent following reoperation for PNH. The factors significantly associated with PNH were: older age, concurrent lymph node dissection, and chronic lymphocytic thyroiditis. Gender, previous neck irradiation, presentation at diagnosis (symptomatic or incidental), substernal goiter, thyroidectomy for hyperthyroidism, prior thyroid surgery, malignant histology, the extent of the surgery (total versus non-total thyroidectomy), the use of energy-based vessel sealing devices, the use of the hemostatic agent Surgicel, and the placement of a surgical drain were not significantly associated with PNH. Conclusion Hematoma after thyroid surgery is an uncommon complication, but it is related to significant postoperative morbidity. A better understanding of the risk factors and of the time until hematoma formation can help target high-risk patients for preventive measures and closer postoperative observation.

19 February 2021 in International Archives of Otorhinolaryngology
Verified
Journal Article
Open access
PDF file
ACAndre de Ywata Carvalho
Andre de Ywata Carvalho
HKHugo Fontan Kohler
Hugo Fontan Kohler
CGCamila Couto Gomes
Camila Couto Gomes
Jose VartanianJose Vartanian
Jose Vartanian
Luiz P. KowalskiLuiz P. Kowalski
Luiz P. Kowalski
Introduction The incidence of papillary thyroid microcarcinoma (PTMC) has increased, and its treatment remains controversial. Objective To identify the clinical and pathological factors predictive of tumor recurrence. Methods We retrospectively analyzed 2,538 consecutive patients treated for PTMC, most submitted to total thyroidectomy (98%) followed by radioactive iodine (RAI) ablation (51.7%) at a cancer center from 1996 to 2015. The patients were stratified according to the American Thyroid Association (ATA) risk categories (low, intermediate, or high), and the clinicopathological features were evaluated by multivariate Cox regression analysis to identify independent prognostic factors for recurrence. Results After a mean follow-up of 58 months (range: 3 to 236.5 months), tumor recurrence was diagnosed in 63 (2.5%) patients, mostly in the lymph nodes. Distant metastasis occurred in 2 (0.1%) patients. There were no cancer-related deaths. The multivariate analysis showed that age < 55 years (p = 0.049; hazard ratio [HR]: 2.54; 95% confidence interval [95%CI]: 0.95 to 0.99), multifocality (p = 0.032; HR: 1.76; 95%CI: 1.05 to 2.96), and the presence of lymph-node metastasis (p < 0.001; HR: 3.69; 95%CI: 2.07–6.57) were independent risk factors for recurrence. Recurrence was observed in 29 (1.5%) out of 1,940 low-risk patients, 32 (5.4%) out of 590 intermediate-risk patients, and in 2 (25%) out of 8 high-risk patients. Conclusions The prognosis of PTMC is excellent, favoring a conservative treatment for most patients. Age < 55 years, multifocality, and node metastasis at diagnosis, as well the ATA staging system effectively predict the risk of recurrence. The presence of these risk factors can help identify patients who should be considered for more aggressive management and more frequent follow-up.

10 April 2024 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
ACAndre Ywata de Carvalho
Andre Ywata de Carvalho
HKHugo Fontan Kohler
Hugo Fontan Kohler
CCCamila C. G. Ywata de Carvalho
Camila C. G. Ywata de Carvalho
Jose VartanianJose Vartanian
Jose Vartanian
Luiz P. KowalskiLuiz P. Kowalski
Luiz P. Kowalski
Objective: Despite a favorable prognosis, some patients with papillary thyroid carcinoma (PTC) develop recurrence. The objective of this study was to examine the impact of the combination of initial American Thyroid Association (ATA) risk stratification with serum level of postoperative stimulated thyroglobulin (s-Tg) in predicting recurrence in patients with PTC and compare the results with an assessment of response to initial therapy (dynamic risk stratification). Subjects and methods: We retrospectively analyzed 1,611 patients who had undergone total thyroidectomy for [...] ABSTRACT Objective: Despite a favorable prognosis, some patients with papillary thyroid carcinoma (PTC) develop recurrence. The objective of this study was to examine the impact of the combination of initial American Thyroid Association (ATA) risk stratification with serum level of postoperative stimulated thyroglobulin (s-Tg) in predicting recurrence in patients with PTC and compare the results with an assessment of response to initial therapy (dynamic risk stratification). Subjects and methods: We retrospectively analyzed 1,611 patients who had undergone total thyroidectomy for

29 July 2025 in Head & Neck
Verified
Journal Article
Open access
ACAndre Ywata de Carvalho
Andre Ywata de Carvalho
FCFelipe D' Almeida Costa
Felipe D' Almeida Costa
JVJose Guilherme Vartanian
Jose Guilherme Vartanian
Luiz P. KowalskiLuiz P. Kowalski
Luiz P. Kowalski
Objective: Solid subtype of papillary thyroid carcinoma (SSPTC) is an uncommon subtype of papillary thyroid cancer (PTC) and its prognostic significance is still controversial. The aim of this review is to present the clinicopathological features of SSPTC and compare its clinical behavior with classical PTC (cPTC). Methods: We retrospectively analyzed patients who underwent thyroidectomy for SSPTC and compared the clinicopathological findings and clinical outcomes with those of patients with cPTC. Results: Among 4937 patients treated for PTC, 63 (1.3%) were diagnosed with SSPTC, of which 76.2% were female, with a median age of 40 years, 3.2% had prior cervical irradiation, and the median diameter of the tumor was 15 mm. Compared to cPTCs, SSPTCs were larger (median tumor diameter: 15 vs. 9 mm), more symptomatic (non‐incidentally discovered) and were associated with an elevated risk for multifocality, extrathyroidal extension, lympho‐vascular invasion, lymph node metastasis, extra‐nodal extension, and distant metastasis. After a mean follow‐up of 58.5 months, rates of biochemical incomplete response to treatment and structural recurrence were higher when compared to those of cPTC. None of the patients who demonstrated an excellent response to treatment presented cancer recurrence during follow‐up. Distant metastasis occurred in 3 patients (4.8%). There were no cancer‐related deaths. Conclusions: SSPTC is an aggressive histological subtype of PTC associated with adverse prognostic features, including larger tumor size, multifocality, and extrathyroidal extension, which correlate with a higher risk of cancer recurrence and therefore should be considered for accurate risk stratification, comprehensive management, and close follow‐up.